An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment ...

Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

In the second article in a series on the leadership benefits of putting employees first, Christine Miller, president and CEO ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

Over the past decade, advances in drug discovery and clinical development have led to a rise in the number of approved therapies, resulting in an increasingly competitive marketplace. These evolving ...

Six of the seven blockbuster biotherapeutics belonging to Big Pharma have roots to small biotechs (see Table 1). So too does Tim Charlebois, Ph.D., VP of technology and innovation strategy within ...

Then: In a 2021 “Companies To Watch” article written by Wayne Koberstein, Carisma Therapeutics CEO Steven Kelly spoke about his three-pronged mandate to fund the (then) privately held company, build a ...

The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering ...

A | VIRTUAL CLINICAL TRIALS (VCTs) PRESENT MANY OPPORTUNITIES, including increased monitoring and compliance, and enhanced opportunities for patients to participate, particularly those in rural areas.